Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.22.215418v1?rss=1 Authors: Tachida, Y., Miura, S., Imamaki, R., Ogasawara, N., Takuwa, H., Sahara, N., Shindo, A., Matsuba, Y., Saito, T., Taniguchi, N., Kawaguchi, Y., Tomimoto, H., Saido, T., Kitazume, S. Abstract: The deposition of amyloid {beta} (A {beta}) in blood vessels of the brain, known as cerebral amyloid angiopathy (CAA), is observed in more than 90% of Alzheimer disease (AD) patients. The presence of such CAA pathology is not as evident, however, in most mouse models of AD, thereby making it difficult to examine the contribution of CAA to the pathogenesis of AD. Since blood levels of soluble amyloid precursor protein (sAPP) in rodents are less than 1% of those in humans, we hypothesized that endothelial APP expression would be markedly lower in rodents, thus providing a reason for the poorly expressed CAA pathology. Here we generated mice that specifically express human APP770 in endothelial cells. These mice exhibited an age-dependent robust deposition of A {beta} in brain blood vessels but not in the parenchyma. Crossing these animals with APP knock-in mice led to an expanded CAA pathology as evidenced by increased amounts of amyloid accumulated in the cortical blood vessels. These results show that both neuronal and endothelial APP contribute cooperatively to vascular A {beta} deposition, and suggest that this mouse model will be useful for studying disease mechanisms underlying CAA and for developing novel AD therapeutics. Copy rights belong to original authors. Visit the link for more info